 Developing novel transdermal CBD treatments to treat patients suffering rare epilepsies and neurological disorders Lead development candidate Zygel offers a potential goldmine of therapies for multiple conditions Zygel is being developed for patients suffering from Fragile X syndrome, a genetic condition that causes learning disabilities What Zynerba does: Zynerba Pharmaceuticals Inc NASDAQ:ZYNE is doing trailblazing work pushing clinical trials for cannabis-derived treatments. The specialty pharma company is developing novel transdermal CBD treatments for patients suffering rare epilepsies and neurological disorders. 